(DCTH) Delcath Systems - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US24661P8077

DCTH: Cancer, Treatment, Chemotherapy, Liver, Delivery, System

Delcath Systems, Inc. (NASDAQ:DCTH), a leader in interventional oncology, specializes in innovative treatments for primary and metastatic liver cancers. The companys flagship product, HEPZATO KIT, represents a significant advancement in targeted chemotherapy delivery. This system combines melphalan with a hepatic delivery mechanism designed to maximize therapeutic impact while minimizing systemic exposure, thereby reducing adverse side effects. HEPZATO is currently under evaluation in the FOCUS clinical trial, which is investigating its efficacy in treating metastatic hepatic dominant Uveal Melanoma, with a primary focus on objective response rate. Beyond its investigational use, Delcath also markets the CHEMOSAT Hepatic Delivery System in Europe, enabling medical centers to administer melphalan for a range of liver cancers under approved indications. Established in 1988, Delcath is headquartered in New York, New York, and maintains a strong presence in both the U.S. and European markets. Web URL: https://www.delcath.com.

From a stock performance perspective, Delcath Systems, Inc. (NASDAQ:DCTH) is currently trading at $13.95, with a 20-day average volume of 335,331 shares. The stocks short-term technical outlook is mixed, as the 20-day SMA ($15.60) and 50-day SMA ($14.03) indicate recent downward pressure, while the 200-day SMA ($10.21) reflects longer-term upside momentum. The ATR of 0.81 signals moderate volatility. On the fundamental side, the companys market cap stands at $538.66M, with a forward P/E of 106.38, reflecting investor expectations of future earnings growth. The P/B ratio of 62.85 highlights a premium valuation relative to book value, while the P/S ratio of 23.79 underscores the markets confidence in the companys revenue potential. However, the lack of reported RoE suggests that profitability remains a key area of focus for investors.

3-Month Forecast: Based on the intersection of and , Delcath Systems, Inc. (NASDAQ:DCTH) is likely to experience volatility in the near term. The stocks recent pullback from the 20-day SMA high of $15.60, coupled with a forward P/E of 106.38, suggests that investor sentiment may be sensitive to clinical trial updates and revenue growth metrics. The ATR of 0.81 indicates that price fluctuations could remain moderate, with potential support near the 50-day SMA of $14.03. However, the high P/B ratio of 62.85 may pose a risk if growth expectations are not met, as investors may reassess valuations. Overall, the stocks trajectory will likely hinge on the progress of the FOCUS trial and the companys ability to expand its market share in interventional oncology.

Additional Sources for DCTH Stock

DCTH Stock Overview

Market Cap in USD 479m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception 2018-05-29

DCTH Stock Ratings

Growth 5y 17.8%
Fundamental -31.9%
Dividend 0.0%
Rel. Strength Industry 216
Analysts 4.67/5
Fair Price Momentum 11.42 USD
Fair Price DCF -

DCTH Dividends

No Dividends Paid

DCTH Growth Ratios

Growth Correlation 3m 48.3%
Growth Correlation 12m 96%
Growth Correlation 5y -36.7%
CAGR 5y 5.82%
CAGR/Max DD 5y 0.06
Sharpe Ratio 12m 0.42
Alpha 200.67
Beta 2.61
Volatility 72.70%
Current Volume 220.8k
Average Volume 20d 314.2k
What is the price of DCTH stocks?
As of March 14, 2025, the stock is trading at USD 12.08 with a total of 220,753 shares traded.
Over the past week, the price has changed by -8.62%, over one month by -25.80%, over three months by -0.25% and over the past year by +215.40%.
Is Delcath Systems a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Delcath Systems (NASDAQ:DCTH) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -31.92 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DCTH as of March 2025 is 11.42. This means that DCTH is currently overvalued and has a potential downside of -5.46%.
Is DCTH a buy, sell or hold?
Delcath Systems has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy DCTH.
  • Strong Buy: 4
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for DCTH stock price target?
According to ValueRays Forecast Model, DCTH Delcath Systems will be worth about 13.5 in March 2026. The stock is currently trading at 12.08. This means that the stock has a potential upside of +11.51%.
Issuer Forecast Upside
Wallstreet Target Price 22.2 83.5%
Analysts Target Price 21.3 76.6%
ValueRay Target Price 13.5 11.5%